BioCentury
ARTICLE | Clinical News

AOP Orphan reports Phase II polycythemia vera data

December 11, 2012 2:12 AM UTC

AOP Orphan Pharmaceuticals AG (Vienna, Austria) reported data from 11 evaluable patients in the Phase II portion of the Phase I/II PEGINVERA trial of its subcutaneous AOP2014 to treat polycythemia vera (PV). The compound produced an overall response rate (ORR) of 91% at 12 months, including five complete responses and five partial responses. Safety data from 41 patients showed that AOP2014 was well tolerated. ...